Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate

Clinical and Experimental Rheumatology

Volumn 32, Issue 4, 2014, Pages 563-571

  Pichlmeier, Uwe ^a   Heuer, Kay Uwe ^a  

^a MEDAC GMBH   (Germany)

Author keywords

Autoinjection; Bioavailability; Rheumatoid arthritis; Subcutaneous methotrexate

Indexed keywords

AMINOTRANSFERASE; ANTIUROLITHIASIS AGENT; BILIRUBIN; CALCIUMFOLINAT GRY; FOLINIC ACID; HEMOGLOBIN; METHOTREXATE; POTASSIUM SODIUM HYDROGEN CITRATE; UNCLASSIFIED DRUG; URALYT U; UROBILINOGEN;

ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOINJECTOR; BLOOD SAMPLING; BLOOD TOXICITY; BODY HEIGHT; BODY MASS; BODY WEIGHT; BURNING SENSATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELEVATED BLOOD PRESSURE; ERYTHROCYTE; ETHNICITY; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HEADACHE; HEMATOMA; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NORMAL HUMAN; OPEN STUDY; PAIN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RACE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; URINALYSIS;

ADMINISTRATION, ORAL; ADULT; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEMALE; GERMANY; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METABOLIC CLEARANCE RATE; METHOTREXATE; MIDDLE AGED; NEEDLES; YOUNG ADULT;

EID: 84904867961     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. BOFFA MJ, CHALMERS RJ: Methotrexate for psoriasis. Clin Exp Dermatol 1996; 21: 399-408.
2. WEINBLATT ME: Efficacy of methotrexate in rheumatoid arthritis. Br J Rheumatol 1995; 34 (Suppl. 2): 43-8.
3. SWIERKOT J, SZECHINSKI J: Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006; 58: 473-92.
4. PAVY S, CONSTANTIN A, PHAM T et al.: Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006; 73: 388-95.
5. DALRYMPLE JM, STAMP LK, O'DONNELL JL, CHAPMAN PT, ZHANG M, BARCLAY ML: Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 3299-308.
6. HERMAN RA, VENG-PEDERSEN P, HOFFMAN J, KOEHNKE R, FURST DE: Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci 1989; 78: 165-71.
7. OGUEY D, KOLLIKER F, GERBER NJ, REI-CHEN J: Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 611-4.
8. LEBBE C, BEYELER C, GERBER NJ, REICHEN J: Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 475-7.
9. HAMILTON RA, KREMER JM: Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 86-90.
10. KURNIK D, LOEBSTEIN R, FISHBEIN E et al.: Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 57-63.
11. HOEKSTRA M, HAAGSMA C, NEEF C, PROOST J, KNUIF A, van de LAAR M: Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 645-8.
12. RAU R: Bioavailability of higher dose MTX comparing oral and subcutaneous administration in patients with RA. J Rheumatol 2005; 32: 1412; author reply 1412-3.
13. STUART JF, CALMAN KC, WATTERS J et al.: Bioavailability of methotrexate: implications for clinical use. Cancer Chemother Pharmacol 1979; 3: 239-41.
14. JUNDT JW, BROWNE BA, FIOCCO GP, STEELE AD, MOCK D: A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845-9.
15. ROZIN A, SCHAPIRA D, BALBIR-GURMAN A et al.: Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. Ann Rheum Dis 2002; 61: 756-7.
16. RAU R, HERBORN G: Benefit and risk of methotrexate treatment in rheumatoid arthritis. Clin Exp Rheumatol 2004; 22: S83-94.
17. BALIS FM, MIRRO J jr., REAMAN GH et al.: Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988; 6: 1882-6.
18. BRAUN J, KASTNER P, FLAXENBERG P et al.: Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58: 73-81.
19. ISLAM MS, HAQ SA, ISLAM MN et al.: Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis. Mymensingh Med J 2013; 22: 483-8.
20. KIVITZ A, COHEN S, DOWD JE, EDWARDS W, THAKKER S, WELLBORNE FR: Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clinical Therapeutics 2006; 28: 1619-29.
21. SCHIFF MH, SIMON LS, DAVE KJ, JAFFE J, FREUNDLICH B: Self-administrated methotrexate using a Medijet auto-injector improves bioavailability compared with oral methotrexate in adults with rheumatoid arthritis. Ann Rheum Dis 2013; 72 (Suppl. 3): 249. [abstract].
22. BHARADWAJ A, AGRAWAL S, BATLEY M, HAMMOND A: Use of parenteral methotrexate significantly reduces the need for biological therapy. Rheumatology (Oxford) 2008; 47: 222.
23. BAKKER MF, JACOBS JW, WELSING PM et al.: Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis 2010; 69: 1849-52.
24. STAMP LK, BARCLAY ML, O'DONNELL JL et al.: Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol 2011; 38: 2540-7.
25. THORNTON C, ONG V, WARD J, KENNEDY N, STEUER A: Comment on: Use of parenteral methotrexate significantly reduces the need for biological therapy. Rheumatology (Oxford) 2008; 47: 1438.
26. PINCUS T, CASTREJON I, BERGMAN MJ, YAZICI Y: Treat-to-target: not as simple as it appears. Clin Exp Rheumatol 2012; 30: S10-20.
27. KREMER JM, LEE JK: The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986; 29: 822-31.
28. MOUTERDE G, BAILLET A, GAUJOUX-VIALA C et al.: Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011; 78: 587-92.
29. WEGRZYN J, ADELEINE P, MIOSSEC P: Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1232-4.
30. RUTKOWSKA-SAK L, RELL-BAKALARSKA M, LISOWSKA B: Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects. Reumatologia 2009; 47: 207-11.
31. Metoject® (methotrexate) 50 mg/mL solution for injection, pre-filled syringe. Summary of Product Characteristics. medac GmbH, Hamburg, Germany. Last modified 12 November 2012. http://www.medicines/org.uk/emc/medicine/22145/SPC. Accessed November 20, 2013.
32. Metoject® (methotrexate) 50 mg/mL solution for injection, pre-filled pen. Summary of Product Characteristics. medac GmbH, Hamburg, Germany. Version date: 03 February 2012.